Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma Published, JLR Papers in Press, March 23, 2006.

Apolipoprotein C-III (apoC-III) is an important regulator of lipoprotein metabolism. Radioisotope and stable isotope kinetic studies show differing results in relation to the kinetics of apoC-III in HDL. Kinetic analysis of HDL apoC-III may be difficult because of its low concentration, as well as the presence of other apoproteins at higher concentration, in the HDL fraction. We used Intralipid® (IL), known to preferentially extract apoC proteins from plasma, as a means of extracting apoC-III from HDL before apoprotein separation by isoelectric focusing gel electrophoresis for the measurement of tracer enrichment. Protein purity was assessed by an isoleucine-to-leucine (Ile/Leu) ratio, as apoC-III contains no isoleucine. We compared apoC-III kinetics in 14 men using a bolus infusion of deuterated leucine. The Ile/Leu ratio for IL-extracted HDL (IL-HDL) apoC-III (3.0 ± 0.7%) was not different from that of VLDL apoC-III (2.6 ± 0.6%) but was significantly lower than that of untreated HDL apoC-III (9.0 ± 2.9%) (P < 0.001). The isotopic enrichment curves and fractional catabolic rates (FCRs) for IL-HDL apoC-III were not different from those of VLDL apoC-III. In contrast, HDL apoC-III had significantly lower isotopic enrichments and FCRs than IL-HDL apoC-III (P < 0.001). In conclusion, this simple IL method can be used to isolate apoC-III from HDL with minimal interference from other HDL apoproteins, and it demonstrates that the kinetics of apoC-III in VLDL and HDL are similar, supporting the concept of a single kinetically homogeneous pool of apoC-III in plasma.

• Publication year

  2006

• Venue

  Journal of Lipid Research

• Publication date

  2006-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1194/jlr.M600018-JLR200PMID 16556931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics

  2005cited by this paper
• Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

  2004cited by this paper
• Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia.

  2004cited by this paper
• Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.

  2003cited by this paper
• New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism

  2002cited by this paper
• Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.

  2002cited by this paper
• Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins.

  2002cited by this paper
• Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.

  2000cited by this paper
• VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial

  2000cited by this paper
• Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis.

  1999cited by this paper
• VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein.

  1998cited by this paper
• Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I.

  1998cited by this paper
• Immunochemical methods for quantification of human apolipoprotein C-III.

  1996cited by this paper
• Apolipoprotein CII from Chicken (Gallus domesticus)

  1996cited by this paper
• Immunologic and Ultrastructural Characterization of HIV Pseudovirions Containing Gag and Env Precursor Proteins Engineered in Insect Cells

  1996cited by this paper
• Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins.

  1993cited by this paper
• Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.

  1991cited by this paper
• Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.

  1989cited by this paper
• Apolipoproteins C-I, C-II, and C-III: kinetics of association with model membranes and intermembrane transfer.

  1988cited by this paper
• Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.

  1988cited by this paper
• Metabolism of apolipoprotein C-III in normolipemic human subjects.

  1988cited by this paper
• Metabolism of apolipoprotein C.

  1986cited by this paper
• Direct determination of apolipoprotein C-III specific activity using immunoaffinity chromatography.

  1986cited by this paper
• Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.

  1985cited by this paper
• Isoproteins of human apolipoprotein A-II: isolation and characterization.

  1983influential reference
• Direct measurement of apoprotein C-III specific activity in 125I-labeled very low density lipoproteins using immunoaffinity chromatography.

  1983cited by this paper
• Activator proteins for lipoprotein lipase from bovine plasma: preparation by adsorption to Intralipid.

  1982cited by this paper
• Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects.

  1981cited by this paper
• Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.

  1981cited by this paper
• Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.

  1981cited by this paper
• Studies on the fat emulsion Intralipid. I. Association of serum proteins to Intralipid triglyceride particles (ITP).

  1980cited by this paper
• Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins.

  1980cited by this paper
• Quantification of apoC-II and apoC-III of human very low density lipoproteins by analytical isoelectric focusing.

  1978cited by this paper
• Selective extraction of human serum very low density apolipoproteins with organic solvents.

  1977cited by this paper
• The Complete Amino Acid Sequence of Alanine Apolipoprotein (apoC-III), an Apolipoprotein from Human Plasma Very Low Density Lipoproteins

  1974cited by this paper
• Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources.

  1973cited by this paper
• The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.

  1972cited by this paper
• The metabolism of very low density lipoprotein proteins. II. Studies on the transfer of apoproteins between plasma lipoproteins.

  1972cited by this paper
• Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

  1972cited by this paper
• Isoelectric fractionation and characterization of polypeptides from human serum very low density lipoproteins.

  1971cited by this paper
• Papers and Notes on I I Methodology One-step Screening Method for the Polymorphism of Apolipoproteins A-i, A-11, and A-iv

  year unknowninfluential reference

• Modeling the postprandial CETP-mediated lipid redistribution between chylomicrons, LDL and HDL

  2025cites this paper
• Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL)

  2020cites this paper
• A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

  2017cites this paper
• Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects.

  2017cites this paper
• Triglyceride‐rich lipoprotein metabolism in women: roles of apoC‐II and apoC‐III

  2016cites this paper
• METABOLISM OF APOLIPOPROTEIN C- II (ApoC-II) IN UREMIC PATIENTS TREATED WITH CHRONICAL HEMODIALYSIS

  2016cites this paper
• Low High-Density Lipoprotein and Risk of Myocardial Infarction

  2015cites this paper
• Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families

  2014cites this paper
• Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein–Proteome Remodeling

  2013cites this paper
• Altered Activation of Endothelial Anti- and Pro-Apoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of HDL-Proteome Remodeling

  2013influential citation
• Influence of dietary fat intake on acute changes in postprandial lipid and lipoprotein expression in children and adolescents with nonalcoholic fatty liver disease (NAFLD)

  2012cites this paper
• Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease

  2011cites this paper
• Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.

  2011cites this paper
• Complexities of plasma apolipoprotein C-III metabolism1

  2011cites this paper
• Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?1

  2011cites this paper
• Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.

  2010cites this paper
• Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins

  2010cites this paper
• Dose-Dependent Effect of Rosuvastatin

  2009cites this paper
• Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

  2008influential citation
• Atorvastatin and Fenofibrate Have Comparable Effects on VLDL–Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome

  2008cites this paper
• Dose-Dependent Effect of Rosuvastatin on VLDL–Apolipoprotein C-III Kinetics in the Metabolic Syndrome

  2008cites this paper
• Dose-Dependent Effect of Rosuvastatin on Very-Low Density Lipoprotein-Apolipoprotein C-III Kinetics in the Metabolic Syndrome

  2008cites this paper
• Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.

  2008cites this paper
• The challenges for molecular nutrition research 4: the “nutritional systems biology level”

  2008cites this paper
• An ABC of apolipoprotein C‐III: a clinically useful new cardiovascular risk factor?

  2008cites this paper
• Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractionss⃞ Published, JLR Papers in Press, February 21, 2007.

  2007cites this paper
• Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans Published, JLR Papers in Press, May 25, 2006.

  2006cites this paper